Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12462243 | 0.92 | NPSR1 (0.41) | MEN1KMT2AP2RX7NPSR1MAPT | |
| SCHEMBL2168136 | 0.91 | BCL6 (0.39) | KMT2AP2RX7NPSR1P2RX3MAPT | |
| SCHEMBL2218318 | 0.91 | KDM4E (0.44) | MEN1KMT2ANPSR1MAPTSYK | |
| SCHEMBL1580038 | 0.91 | MAPT (0.40) | MEN1KMT2AALDH1A1TSHRNPSR1 | |
| SCHEMBL2218561 | 0.89 | P2RX7 (0.38) | P2RX7NPSR1ABCG2 | |
| SCHEMBL2218317 | 0.88 | NPSR1 (0.39) | MEN1KMT2ANPSR1P2RX3MAPT | |
| SCHEMBL1581978 | 0.88 | P2RX3 (0.37) | ALDH1A1P2RX7NPSR1P2RX3MAPT | |
| SCHEMBL2216144 | 0.88 | NPSR1 (0.50) | MEN1KMT2AALDH1A1TSHRNPSR1 | |
| SCHEMBL15887163 | 0.87 | MAPT (0.41) | MEN1KMT2ATSHRNPSR1MAPT | |
| SCHEMBL12515493 | 0.86 | NPSR1 (0.38) | MEN1KMT2AALDH1A1NPSR1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310388-B1 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | PASTEUR INSTITUT KOREA (KR) | 2015-08-05 | — | — | EP | claimed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | claimed |
| EP-2310388-B1 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | PASTEUR INSTITUT KOREA (KR) | 2015-08-05 | — | — | EP | disclosed |
| EP-2310388-B1 | PYRIDOPYRIMIDINE COMPOUNDS AS ANTI-TUBERCULAR AGENTS | PASTEUR INSTITUT KOREA (KR) | 2015-08-05 | — | — | EP | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730576-A2 | Anti-infective compounds | Institut Pasteur Korea (KR) | 2014-05-14 | — | — | EP | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | NO ZAESUNG (KR) | 2013-01-10 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| WO-2011085990-A1 | ANTI - INFECTIVE PYRIDO (1,2 -A) PYRIMIDINES | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2010003533-A2 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | MEN1 3685/4885KMT2A 4781/4885ALDH1A1 3932/4885 |
| US-20130012506-A1 | ANTI-INFECTIVE PYRIDO (1,2-A) PYRIMIDINES | TYMS, TYMP, DCTPP1 | MEN1 3613/4885KMT2A 4390/4885ALDH1A1 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.